Abstract 2035P
Background
Multiple international guidelines suggest that pre-treatment cardiac markers should be taken prior to each cycle of treatment to support the early diagnosis and treatment of immune checkpoint inhibitor (ICI) induced myocarditis (1). As a large regional tertiary cancer centre with an established cardio-oncology service early adoption of baseline and subsequent cardiac surveillance has been implemented and its utility evaluated.
Methods
A retrospective analysis of patients whom had undergone baseline cardiac assessment prior to receiving ICI treatment at the Clatterbridge Cancer Centre between October 2022 and March 2023 was performed. Within the regional protocol all patients with abnormal cardiac markers (Pro-B Naturetic Peptide (Pro-BNP) >400 ng/L and or a high sensitivity troponin T (TropT) >14 ng/L) were subsequently monitored with pre-cycle cardiac biochemical monitoring for the first 3 cycles of ICI treatment.
Results
400 patients who commenced ICI treatment underwent baseline cardiac screening. Of these 169 patients (42.2%) had abnormal biomarkers: 36% (n=61) elevated TropT; 32% (n=54) elevated pro-BNP and 32% (n=54) had elevations in both. Within this cohort 3.3% (n=13) patients were diagnosed with ICI-induced myocarditis; 12 confirmed on cardiac MRI (cMRI) and 1 clinically diagnosed due to clinical instability. Of these 69% (n=9) patients had abnormal baselines and thus had pre-cycle monitoring; 4 did not. Of these 9; 8 were detected through symptoms alone; 1 patient was found to have elevated biomarkers but had already been clinically assessed prior to treatment and had been admitted prior to the biomarker results being reviewed.
Conclusions
Baseline cardiac assessment is useful, as the majority of patients that go on to develop ICI myocarditis have abnormal baseline values. However, the clinical utility of pre-cycle screening has not demonstrated enhanced or earlier detection of myocarditis compared to clinical assessment and represents an area of potential cost saving. Patients are either presenting mid-cycle or are identified via symptomatic review therefore investment is better placed in education and training to optimize clinical recognition and timely management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Dobson: Financial Interests, Personal, Invited Speaker: BMS, Roche. N. Garbutt: Financial Interests, Personal, Invited Speaker: BMS. T. Guinan: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche, Sanofi. A.C. Olsson-Brown: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche, Novartis, AZ, Eisai, B-I. All other authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06